Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program

被引：0
|
作者：
Musto, P.
Maurillo, L.
Spagnoli, A.
D'Arco, A.
Pollio, B.
Candoni, A.
Spiriti, A. Aloe
Lunghi, M.
Fili, C.
Orciuolo, E.
Venditti, A.
Morabito, F.
Mazza, P.
Pastore, D.
Santini, V.
机构：
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70197-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 50 条
  • [1] Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes
    Musto, Pellegrino
    Maurillo, Luca
    Spagnoli, Alessandra
    Gozzini, Antonella
    Rivellini, Flavia
    Lunghi, Monia
    Villani, Oreste
    Aloe-Spiriti, Maria Antonietta
    Venditti, Adriano
    Santini, Valeria
    [J]. CANCER, 2010, 116 (06) : 1485 - 1494
  • [2] Azacitidine in lower-risk myelodysplastic syndromes
    Santini, Valeria
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S22 - S26
  • [3] 5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
    Musto, P.
    Maurillo, L.
    Spagnoli, A.
    Gozzini, A.
    Rivellini, F.
    Tatarelli, C.
    Lunghi, M.
    Fili, C.
    Orciuolo, E.
    Ciuffreda, L.
    Vigna, E.
    Della Cioppa, P.
    Ferrero, D.
    Palmieri, S.
    Palumbo, G.
    Di Renzo, N.
    Oliva, E.
    Sanpaolo, G.
    Pastore, D.
    Tonso, A.
    Santagostino, A.
    Villani, O.
    D'Auria, F.
    D'Arco, A.
    Gaidano, G.
    Galimberti, S.
    Russo, D.
    Venditti, A.
    Aloe-Spiriti, M. A.
    Leone, G.
    Santini, V.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 368 - 368
  • [4] 5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
    Maurillo, L.
    Spagnoli, A.
    Gozzini, A.
    Cecconi, N.
    D'Argenio, M.
    Lunghi, M.
    Rocco, S.
    Palumbo, G.
    Rivellini, E.
    Genuardi, M.
    Sibilla, S.
    Ferrara, F.
    Mele, G.
    Filardi, N.
    Sanpaolo, G.
    Specchia, G.
    Tonso, A.
    Santagostino, A.
    Voso, M. T.
    Balleari, E.
    Cassibba, V.
    Della Cioppa, P.
    Mazzone, C.
    Oliva, E.
    Ciuffreda, L.
    Russo, D.
    Galimberti, S.
    Villani, O.
    D'Auria, F.
    Di Renzo, N.
    D'Arco, A. M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 96 - 96
  • [5] 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program
    Musto, Luca Maurillo
    Spagnoli, Alessandra
    Gozzini, Antonella
    Rivellini, Flavia
    Tatarelli, Caterina
    Lunghi, Monia
    Fili, Carla
    Orciuolo, Enrico
    Ciuffreda, Lucia
    Vigna, Ernesto
    Della Cioppa, Paola
    Candoni, Anna
    Ferrero, Dario
    Palmieri, Salvatore
    Palumbo, Giuseppe
    Di Renzo, Nicola
    Oliva, Esther
    Sanpaolo, Grazia
    Pastore, Domenico
    Tonso, Anna
    Santagostino, Alberto
    Rocco, Stefano
    Villani, Oreste
    D'Auria, Fiorella
    D'Arco, Alfonso Maria
    Gaidano, Gianluca
    Galimberti, Sara
    Russo, Domenico
    Venditti, Adriano
    Aloe-Spiriti, Maria Antonietta
    Leone, Giuseppe
    Santini, Valeria
    [J]. BLOOD, 2008, 112 (11) : 926 - 927
  • [6] Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program
    Abouyahya, Imane
    Alhan, Canan
    Westers, Theresia M.
    te Boekhorst, Peter A.
    Kappers-Klunne, Mies C.
    Coenen, Jules L.
    Heyning, Fenna H.
    Huls, Gerwin A.
    de Wolf, Joost T.
    Imholz, Alex L.
    Koene, Harry R.
    Veth, Gerda
    de Kruijf, Evert-Jan F. M.
    Muus, Petra
    Planken, Erwin V.
    Segeren, Christine M.
    Vasmel, Wies L.
    van der Velden, Ankie M.
    Velders, Gerjo A.
    Koedam, Jan
    Ossenkoppele, Gert J.
    van de Loosdrecht, Arjan A.
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 874 - 877
  • [7] Treatment of Lower Risk Myelodysplastic Syndromes
    Santini, Valeria
    [J]. HEMATO, 2022, 3 (01): : 153 - 162
  • [8] Treatment of lower risk myelodysplastic syndromes
    Park, Sophie
    [J]. BULLETIN DU CANCER, 2023, 110 (11) : 1156 - 1161
  • [9] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2008, 112 (11) : 88 - 89
  • [10] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
12345